^
Association details:
Biomarker:FGFR3 K650
Cancer:Multiple Myeloma
Drug:bortezomib (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Bortezomib Therapeutic Effect is Associated with Expression of FGFR3 in Multiple Myeloma Cells

Excerpt:
...results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression…Most interestingly, K650E transfectants remain as sensitive to bortezomib as the parental cells....Apoptosis was less prevalent in Y373C mutant and wild-type FGFR3-transfected cells as compared to parental and K650E tranfectants. These results confirm a drug resistance phenotype in Y373C and wild-type transfectant in contrast to a conserved sensitive phenotype in K650E transfectant, which is similar to the parental cells.